Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
2.670
+0.020 (0.75%)
Jul 28, 2025, 4:00 PM - Market closed

Company Description

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.

It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.

Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Taysha Gene Therapies, Inc.
Taysha Gene Therapies logo
CountryUnited States
Founded2019
IPO DateSep 24, 2020
IndustryBiotechnology
SectorHealthcare
Employees73
CEOSean Nolan

Contact Details

Address:
3000 Pegasus Park Drive, Suite 1430
Dallas, Texas 75247
United States
Phone214 612 0000
Websitetayshagtx.com

Stock Details

Ticker SymbolTSHA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001806310
CUSIP Number877619106
ISIN NumberUS8776191061
Employer ID84-3199512
SIC Code2836

Key Executives

NamePosition
Sean P. NolanChief Executive Officer and Chairman
Dr. Sukumar Nagendran M.D.President, Head of Research and Development and Director
Kamran Alam CPA, M.B.A.Chief Financial Officer and Corporate Secretary
Hayleigh CollinsDirector of Corporate Communications and Investor Relations
Tracy M. Porter SPHRChief People Officer
Frederick Porter Ph.D.Chief of Staff and Technical Operations Officer
Emily McGinnis M.P.H.Chief Patient and External Affairs Officer
Sean McAuliffeChief Business Officer
Dr. Steven Gray Ph.D.Chief Scientific Advisor of UT Southwestern Gene Therapy Program
Berge Minassian M.D.Chief Medical Advisor of UT Southwestern Gene Therapy Program

Latest SEC Filings

DateTypeTitle
Jul 16, 2025SCHEDULE 13G/AFiling
Jul 3, 2025SCHEDULE 13GFiling
Jun 3, 2025SCHEDULE 13D/AFiling
Jun 3, 20258-KCurrent Report
May 29, 20258-KCurrent Report
May 29, 2025424B5Filing
May 29, 20258-K/A[Amend] Current report
May 28, 2025424B5Filing
May 28, 20258-KCurrent Report
May 15, 202510-QQuarterly Report